Burns Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Burns Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 3, 8, 1, 24, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

Adial Pharmaceuticals Inc
Aegle Therapeutics Corp
AlgiPharma AS
Alliance Pharma Plc
Alloksys Life Sciences BV
Amniotics AB
Anterogen Co Ltd
Bioharmony Therapeutics Inc
Biomendics LLC
CFM Pharma Holding BV
Chrysalis BioTherapeutics Inc
Claritas Pharmaceuticals Inc
Clene Inc
cStem Regeneration Pharmaceutical Co Ltd
Energenesis Biomedical Co Ltd
FirstString Research Inc
FortuneRock (China) Ltd
GNT Pharma Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Hypo-Stream Ltd
Imagine Pharma LLC
Jupiter Wellness Inc
Kala Pharmaceuticals Inc
Madam Therapeutics BV
Marizyme Inc
Maxwell Biosciences Inc
MediWound Ltd
MicroCures Inc
NeoMatrix Therapeutics Inc
NextPhase Therapeutics
Oxacell AG
Phagelux Inc
Pharmaxis Ltd
QBiotics Group Ltd
Recce Pharmaceuticals Ltd
Regeneus Ltd
Rejuvenation Technologies Inc
Riptide Bioscience Inc
Se-cure Pharmaceuticals Ltd
Shulov Innovative Science Ltd
Stemsynergy Therapeutics Inc
TGV-Inhalonix Inc
Theragnostic Technologies Inc
TreeFrog Therapeutics SAS
USV Pvt Ltd
viDA Therapeutics Inc
Washburn Therapeutics Inc